C91.30 Prolymphocytic leukemia of B-cell type not having achieved remission

Name of the Condition

• Prolymphocytic leukemia of B-cell type not having achieved remission
• ICD-10 Code: C91.30

Summary

Prolymphocytic leukemia of B-cell type (B-PLL) is a rare, aggressive form of chronic lymphoid leukemia characterized by the uncontrolled proliferation of mature B lymphocytes. It primarily affects the blood, bone marrow, and lymphoid tissues, leading to high white blood cell counts and organ infiltration. Unlike other B-cell leukemias, B-PLL progresses rapidly and often does not respond to standard therapies, resulting in a poor prognosis if remission is not achieved.

Causes

The exact cause of B-PLL is not fully understood, but it involves genetic mutations in B lymphocytes that disrupt normal cell regulation. Contributing factors may include environmental exposures, genetic predispositions, and alterations in immune system function. The condition is distinguished by the accumulation of prolymphocytes—larger, more immature-appearing cells than those seen in chronic lymphocytic leukemia (CLL)—which drive its aggressive behavior.

Risk Factors

• Increasing age (most common in adults over 60)
• Prior history of CLL or other lymphoid malignancies
• Certain genetic abnormalities (e.g., translocations involving chromosome 14)
• Exposure to chemotherapy or radiation (less clearly established)

Symptoms

• Rapid onset of fatigue and weakness
• Significant lymphadenopathy (swollen lymph nodes)
• Enlarged spleen or liver (splenomegaly/hepatomegaly)
• Frequent infections due to impaired immune function
• Unexplained weight loss
• Easy bruising or bleeding (thrombocytopenia)
• Night sweats or fever

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to assess cell counts and identify abnormal prolymphocytes. A bone marrow biopsy is typically performed to confirm the presence of clonal B-cell proliferation. Flow cytometry and immunophenotyping are used to distinguish B-PLL from other B-cell leukemias, while cytogenetic testing may identify associated genetic abnormalities. Imaging studies (e.g., CT scans) may assess organ involvement.

Treatment Options

Treatment focuses on controlling disease progression and managing symptoms. Options may include targeted therapies (e.g., BCR inhibitors), chemotherapy, or immunotherapy. Stem cell transplantation may be considered for eligible patients. Supportive care, such as blood transfusions or antibiotics, addresses complications like anemia or infections. Response to treatment is closely monitored, as B-PLL often resists standard therapies.

Prognosis and Follow-Up

Prognosis for B-PLL is generally poor, especially if remission is not achieved. Median survival is shorter than in other B-cell leukemias due to its aggressive nature. Follow-up involves regular blood tests, bone marrow evaluations, and imaging to detect relapse or progression. Palliative care may be integrated to manage symptoms and improve quality of life.

Complications

• Severe infections from impaired immune function
• Anemia or thrombocytopenia leading to bleeding
• Organ failure due to infiltration (e.g., liver, spleen)
• Transformation to more aggressive lymphoma
• Treatment-related toxicities (e.g., from chemotherapy)

Lifestyle & Prevention

No specific preventive measures exist, as the cause is largely unknown. Maintaining overall health, avoiding known carcinogens (e.g., tobacco, excessive radiation), and promptly addressing infections may support immune function. Regular medical check-ups are recommended for those with risk factors.

When to Seek Professional Help

Seek immediate care for symptoms like unexplained weight loss, persistent fever, severe fatigue, or signs of bleeding/bruising. Urgent evaluation is needed if lymph nodes, liver, or spleen become rapidly enlarged, or if infections occur frequently.

Tips for Medical Coders

Code C91.30 is specific to B-cell prolymphocytic leukemia that has not achieved remission. Documentation should clearly indicate the absence of remission status and confirm B-cell lineage. Ensure differentiation from other B-cell leukemias (e.g., CLL) and verify that the condition is active (not in remission) to justify this code.